Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors

Figure 2

Early Cg A response as potential predictor of treatment outcome. In the RADIANT-1 study, patients with early Cg A response experience longer median progression-free survival (13.31 months) (a), whereas median overall survival is 24.90 months (b) [82]. A study in patients with NF-pNETs shows that a reduction of Cg A concentration is correlated with better prognosis in this group of patients (c) [71].

(a)

(b)

(c)